These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients. Ozkok S; Karakoyun-Celik O; Goksel T; Mogulkoc N; Yalman D; Gok G; Bolukbasi Y Lung Cancer; 2008 Dec; 62(3):326-33. PubMed ID: 18482780 [TBL] [Abstract][Full Text] [Related]
3. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635 [TBL] [Abstract][Full Text] [Related]
4. The role of palliative thoracic radiotherapy in non-small cell lung cancer. Brundage MD; Bezjak A; Dixon P; Grimard L; Larochelle M; Warde P; Warr D Can J Oncol; 1996 Feb; 6 Suppl 1():25-32. PubMed ID: 8853535 [TBL] [Abstract][Full Text] [Related]
6. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. Bonner JA; McGinnis WL; Stella PJ; Marschke RF; Sloan JA; Shaw EG; Mailliard JA; Creagan ET; Ahuja RK; Johnson PA Cancer; 1998 Mar; 82(6):1037-48. PubMed ID: 9506347 [TBL] [Abstract][Full Text] [Related]
7. The role of radiotherapy in lung cancer: where is the evidence? Jassem J Radiother Oncol; 2007 May; 83(2):203-13. PubMed ID: 17482301 [TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. van den Hout WB; Kramer GW; Noordijk EM; Leer JW J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480 [TBL] [Abstract][Full Text] [Related]
9. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study. Baldini E; Silvano G; Tibaldi C; Campoccia S; Cionini L; Conte P Semin Oncol; 2000 Feb; 27(1 Suppl 1):28-32. PubMed ID: 10697041 [TBL] [Abstract][Full Text] [Related]
10. The contemporary role of radiation therapy in the management of lung cancer. Mehta MP Surg Oncol Clin N Am; 2000 Jul; 9(3):539-61, ix. PubMed ID: 10853141 [TBL] [Abstract][Full Text] [Related]
11. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233 [TBL] [Abstract][Full Text] [Related]
12. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M; J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967 [TBL] [Abstract][Full Text] [Related]
13. [Current progress in the radiotherapeutic treatment of non-small-cell lung cancer]. Van Houtte P Rev Med Brux; 1995; 16(1):14-9. PubMed ID: 7701161 [TBL] [Abstract][Full Text] [Related]
14. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975 [TBL] [Abstract][Full Text] [Related]
15. ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. Rosenzweig KE; Movsas B; Bradley J; Gewanter RM; Gopal RS; Komaki RU; Kong FM; Lee HK; Feins RH; Langer CJ J Am Coll Radiol; 2009 Feb; 6(2):85-95. PubMed ID: 19179235 [TBL] [Abstract][Full Text] [Related]
18. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer. Ajlouni M; Chapman R; Kim JH Cancer J Sci Am; 1996; 2(6):314-20. PubMed ID: 9166551 [TBL] [Abstract][Full Text] [Related]
19. Concurrent end-phase boost high-dose radiation therapy for non-small-cell lung cancer with or without cisplatin chemotherapy. Graham PH; Clark C; Abell F; Browne L; Capp A; Clingan P; De Sousa P; Fox C; Links M Australas Radiol; 2006 Aug; 50(4):342-8. PubMed ID: 16884421 [TBL] [Abstract][Full Text] [Related]
20. [Current approaches to the use of radiotherapy in patients with non-small-cell lung cancer]. Goldobenko GV; Kanaev SV Vopr Onkol; 1998; 44(5):623-8. PubMed ID: 9884730 [No Abstract] [Full Text] [Related] [Next] [New Search]